Utah Medical Products
UTMD
85 hedge funds and large institutions have $231M invested in Utah Medical Products in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
8% more funds holding
Funds holding: 79 → 85 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.03% less ownership
Funds ownership: 71.33% → 70.29% (-1%)
11% less capital invested
Capital invested by funds: $260M → $231M (-$29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.07M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.47M |
| 3 |
JP Morgan Chase
New York
|
+$1.35M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$1.2M |
| 5 |
Two Sigma Advisers
New York
|
+$487K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.91M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.18M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$570K |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$465K |
| 5 |
Goldman Sachs
New York
|
-$370K |
UTMD Hedge Fund Activity: Q1 2022 in Review
85 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q1 2022, worth a combined $231M — down 11% from $260M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new UTMD positions and 6 closed out — a net gain of 6 holders — while 31 added to existing stakes and 27 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $2.07M. The largest seller was Fidelity Investments, cutting an estimated $7.91M.
- 85 institutional investors held Utah Medical Products (UTMD) as of Q1 2022, up from 79 in Q4 2021.
- Funds reported $231M of Utah Medical Products stock for Q1 2022, down 11% quarter-over-quarter.
- 12 funds opened new Utah Medical Products positions in Q1 2022 and 6 closed out, a net change of +6 holders.
- The largest Utah Medical Products buyer in Q1 2022 was T. Rowe Price Associates, an estimated $2.07M added.
- The largest Utah Medical Products seller in Q1 2022 was Fidelity Investments, an estimated $7.91M sold.
Based on aggregated 13F filings for Q1 2022.